We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why Viking Therapeutics, Inc. (VKTX) Fell More Than Broader Market
Read MoreHide Full Article
In the latest trading session, Viking Therapeutics, Inc. (VKTX - Free Report) closed at $24.42, marking a -5.48% move from the previous day. The stock fell short of the S&P 500, which registered a loss of 0.52% for the day. At the same time, the Dow lost 1.24%, and the tech-heavy Nasdaq lost 0.21%.
Shares of the company witnessed a loss of 29.71% over the previous month, trailing the performance of the Medical sector with its gain of 3.23%, and the S&P 500's loss of 1.21%.
The upcoming earnings release of Viking Therapeutics, Inc. will be of great interest to investors. The company's earnings report is expected on October 28, 2026. The company's upcoming EPS is projected at -$1, signifying a 23.46% drop compared to the same quarter of the previous year.
For the full year, the Zacks Consensus Estimates project earnings of -$4.46 per share and a revenue of $0 million, demonstrating changes of -39.81% and 0%, respectively, from the preceding year.
Any recent changes to analyst estimates for Viking Therapeutics, Inc. should also be noted by investors. Such recent modifications usually signify the changing landscape of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.16% increase. Currently, Viking Therapeutics, Inc. is carrying a Zacks Rank of #2 (Buy).
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 103, this industry ranks in the top 42% of all industries, numbering over 250.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
View the Zacks #1 Rank List
Image: Bigstock
Here's Why Viking Therapeutics, Inc. (VKTX) Fell More Than Broader Market
In the latest trading session, Viking Therapeutics, Inc. (VKTX - Free Report) closed at $24.42, marking a -5.48% move from the previous day. The stock fell short of the S&P 500, which registered a loss of 0.52% for the day. At the same time, the Dow lost 1.24%, and the tech-heavy Nasdaq lost 0.21%.
Shares of the company witnessed a loss of 29.71% over the previous month, trailing the performance of the Medical sector with its gain of 3.23%, and the S&P 500's loss of 1.21%.
The upcoming earnings release of Viking Therapeutics, Inc. will be of great interest to investors. The company's earnings report is expected on October 28, 2026. The company's upcoming EPS is projected at -$1, signifying a 23.46% drop compared to the same quarter of the previous year.
For the full year, the Zacks Consensus Estimates project earnings of -$4.46 per share and a revenue of $0 million, demonstrating changes of -39.81% and 0%, respectively, from the preceding year.
Any recent changes to analyst estimates for Viking Therapeutics, Inc. should also be noted by investors. Such recent modifications usually signify the changing landscape of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.16% increase. Currently, Viking Therapeutics, Inc. is carrying a Zacks Rank of #2 (Buy).
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 103, this industry ranks in the top 42% of all industries, numbering over 250.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.